Gilead's Kite Pharma, Daiichi Sankyo announce partnership revision

Dec. 08, 2022 2:44 AM ETDaiichi Sankyo Company, Limited (DSKYF), DSNKY, GILDBy: Meghavi Singh, SA News Editor1 Comment
  • Kite Pharma, a Gilead Company (NASDAQ:GILD), and Daiichi Sankyo Co., Ltd. (OTCPK:DSNKY) jointly announced the revision of their 2017 partnership pact, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta in Japan.
  • Kite was acquired by Gilead Sciences (

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.